mRNA Vaccine Market Broadens Beyond COVID-19
The global messenger RNA (mRNA) vaccine market is entering a new commercialization phase, expanding beyond COVID-19. The market is projected for significant growth in the coming years.
The global messenger RNA (mRNA) vaccine market is transitioning into a new phase of commercialization, extending its reach beyond COVID-19 to encompass RSV, seasonal influenza, combination respiratory vaccines, pandemic preparedness, emerging infectious diseases, and therapeutic oncology.
The market is estimated at approximately USD 6.3 billion in 2025, with future growth increasingly supported by non-COVID indications. Moderna and Pfizer/BioNTech remain the leading commercial players, while GSK, Arcturus Therapeutics, and Daiichi Sankyo are intensifying competition through differentiated platforms and pipeline expansion.
Approved products including COMIRNATY, SPIKEVAX, and MRESVIA demonstrate growing regulatory validation across multiple vaccine categories. Competitive differentiation is increasingly focused on efficacy, durability, safety, antigen breadth, dose efficiency, thermostability, combination potential, and manufacturing economics.
Future advancements are expected to be driven by self-amplifying RNA technologies, advanced lipid nanoparticle systems, and multivalent formulations. Long-term market leadership will depend on building scalable, multi-indication mRNA franchises with strong clinical and commercial differentiation.